NetWorth
LeaderPortfolio
family
Wilhelm Beier & family
Rank #1265
GERMANY•Healthcare•Pharmaceuticals

Wilhelm Beier & family

Net Worth
$3.38B
+1.59% (24h)
Wilhelm Beier, a self-made billionaire, is the chairman of the supervisory board of Dermapharm, a German pharmaceutical company he founded in 1991. His primary source of wealth comes from his stake in Dermapharm, which manufactures generic drugs and is involved in parallel trade. With a net worth of $3.1 billion as of 2024, Beier's career has been marked by strategic business decisions and family involvement in key operational roles, contributing to his considerable wealth. His entrepreneurial spirit has led Dermapharm to expand into new areas, including medical marijuana and home shopping, showcasing his adaptability in the healthcare industry.

How to read Wilhelm Beier & family's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Wilhelm Beier & family, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $3.38B alongside global rank #1265, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (GERMANY) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Wilhelm Beier was born on April 21, 1956, in Eicherscheid, Germany. Little is known about his early life and education prior to his career in the pharmaceutical industry.

Rise to Success

Beier founded Dermapharm Holding SE in 1991, after gaining experience in the pharmaceutical sector since 1981. Dermapharm has grown into a leading German pharmaceutical manufacturer specializing in the manufacture and marketing of patent-free pharmaceuticals. A significant milestone in Dermapharm's journey came in October 2020, when the company commenced production of the COVID-19 vaccine, Comirnaty, on behalf of BioNTech. Dermapharm went public in 2018. In addition to its pharmaceutical business, Dermapharm holds a significant stake in a home shopping television channel, demonstrating diversification into consumer media.

Key Business Strategies

Beier's business strategy is based on an integrated business model, from product development and manufacturing to quality control and distribution. Dermapharm focuses on selected therapeutic areas and has a significant presence in Germany. A substantial portion of Dermapharm's revenue comes from parallel trade, leveraging price differences across European markets.

Philanthropy

Specific details about Beier's philanthropy initiatives are not readily available in public sources. However, as a high-profile individual, it is likely he is involved in various charitable activities. The precise amounts and beneficiaries are not publicly disclosed.

Career Timeline

2020

COVID-19 Vaccine Production

Dermapharm began producing the COVID-19 vaccine Comirnaty for BioNTech.

2018

Dermapharm IPO

Dermapharm Holding SE went public, increasing market visibility.

2017

Chairman of the Supervisory Board

Appointed chairman of the supervisory board of Dermapharm.

1991

Founded Dermapharm

Founded Dermapharm Holding SE, a German pharmaceutical company.

1981

Pharmaceuticals Career

Began career in the pharmaceuticals industry, holding various positions.

Philanthropic Impact

UnknownUndisclosed

Not Available

Details of philanthropic activities are not publicly available.

Key Business Ventures & Holdings

CompanyStakeValue
Dermapharm Holding SE70.00%$2.17M

Net Worth History

In-Depth Analysis

Early Life

Wilhelm Beier was born on April 21, 1956, in Eicherscheid, Germany. Little is known about his early life and education prior to his career in the pharmaceutical industry.

Rise to Success

Beier founded Dermapharm Holding SE in 1991, after gaining experience in the pharmaceutical sector since 1981. Dermapharm has grown into a leading German pharmaceutical manufacturer specializing in the manufacture and marketing of patent-free pharmaceuticals. A significant milestone in Dermapharm's journey came in October 2020, when the company commenced production of the COVID-19 vaccine, Comirnaty, on behalf of BioNTech. Dermapharm went public in 2018. In addition to its pharmaceutical business, Dermapharm holds a significant stake in a home shopping television channel, demonstrating diversification into consumer media.

Key Business Strategies

Beier's business strategy is based on an integrated business model, from product development and manufacturing to quality control and distribution. Dermapharm focuses on selected therapeutic areas and has a significant presence in Germany. A substantial portion of Dermapharm's revenue comes from parallel trade, leveraging price differences across European markets.

Philanthropy

Specific details about Beier's philanthropy initiatives are not readily available in public sources. However, as a high-profile individual, it is likely he is involved in various charitable activities. The precise amounts and beneficiaries are not publicly disclosed.

Data Sources & Methodology

Figures for Wilhelm Beier & family are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom